Anthony Alexander
Family · Springfield, MONPI 1831676287
Payments from drug & device makers
Across 161 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$433
- E.r. Squibb & Sons, L.L.C.$394
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$282
- Otsuka America Pharmaceutical, Inc.$281
- Teva Pharmaceuticals USA, Inc.$208
- Axsome Therapeutics, Inc.$205
- plus $900 from 10 others
What the payments were for
- Food & beverage$2,62797%
- Education$743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $433 |
| E.r. Squibb & Sons, L.L.C. | 17 | $394 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $282 |
| Otsuka America Pharmaceutical, Inc. | 16 | $281 |
| Teva Pharmaceuticals USA, Inc. | 12 | $208 |
| Axsome Therapeutics, Inc. | 18 | $205 |
| Vanda Pharmaceuticals Inc. | 9 | $185 |
| Alkermes, Inc. | 8 | $153 |
| Johnson & Johnson | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $128 |
| Lundbeck LLC | 5 | $103 |
| Neurocrine Biosciences, Inc. | 3 | $69 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Braeburn Inc. | 2 | $33 |
| Indivior Inc. | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
How this compares
$2,702 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 32 | $54,077 |
| VraylarCariprazine Hcl | 29 | $37,614 |
| CaplytaLumateperone Tosylate | 19 | $32,238 |
| TrintellixVortioxetine Hydrobromide | 25 | $11,570 |
| Oxcarbazepine | 29 | $1,165 |
| Buprenorphine Hcl | 14 | $1,068 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,037 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 43 | $928 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $888 |
| Mirtazapine | 95 | $846 |
| Risperidone | 28 | $845 |
| Doxepin Hcl | 17 | $797 |
| Aripiprazole | 26 | $789 |
| Duloxetine Hcl | 16 | $559 |
| Alprazolam | 57 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $281 | $54,07732 claims |
| AbbVieVraylar | $433 | $37,61429 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $282 | $32,23819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $128 | $11,57025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.
Other family in Springfield
- Laura HedigerSpringfield$71K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.